This recombinant monoclonal antibody is developed as a research-grade biosimilar to HLX-51, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor primarily expressed on activated T cells that plays a critical role in T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes long-term T cell memory formation. TNFRSF4 signaling is implicated in various immune-related conditions, including autoimmune diseases, inflammatory disorders, and cancer, where it serves as a key regulator of immune checkpoint pathways.
HLX-51 represents an investigational therapeutic antibody designed to modulate TNFRSF4 activity, with potential applications in immuno-oncology research. This biosimilar antibody provides researchers with a valuable tool for investigating OX40 signaling mechanisms, studying T cell activation and differentiation, and exploring novel immunotherapeutic strategies. It supports studies examining the role of costimulatory pathways in tumor immunity, autoimmune pathogenesis, and vaccine responses.
Email: support@cusabio.com
Distributors Worldwide